Follow us on  LinkedFit for Health LinkedIN

Frequently Asked Questions (FAQ) - EDCTP Webinar

Cofunding (3)

Answer: 

Cofunding can be provided by either public or private legal entities from across the world, including the institution of the lead applicant. Please note however that one of the EDCTP objectives is to promote international research cooperation.

Answer: 

Funding from WHO can be considered as cofunding (additional funding on top of the EDCTP grant amount).

Answer: 

No, the term cofunding refers to funding for the project in addition to the requested EDCTP funding or awarded grant amount.

Cofunding is not required for projects for which EDCTP2 grants are sought (i.e. EDCTP will reimburse 100% of eligible costs) but it is encouraged. If an applicant has secured cofunding for the project, this can be documented at the proposal stage with letters of commitment from other funder(s).

Specifically for the current call 'Strategic actions supporting large-scale clinical trials', all organisations that provide cofunding should address an official letter to the Coordinator and these should be submitted by the Coordinator at the Letter of Intent application stage (the electronic form for this call for proposals allows for this). The letter of any cofunder should state the name and organisation of the Coordinator; the title of the EDCTP proposal and the EDCTP call to which the proposal has been submitted. In the Budget and Cofunding section of the application form, the applicant can provide an explanation with details on the committed funds, the timeframe for the commitment and any conditions or restrictions on the funding. Demonstration of major support from other funders at the level of the large-scale clinical trial will be taken into account during the evaluation of the “Impact” criterion.

Answer: 

Swiss legal entities are considered entities from a third country not associated to Horizon 2020. This means that Swiss legal entities can participate in EDCTP-funded projects but are not eligible to receive funding and will not count towards the minimum number of legal entities required for a proposal (see the specific eligibility criteria for each call for proposals).

For more information on funding by the Swiss government for Swiss participants in projects related to Horizon2020 or Article 185 Initiatives, please see: http://www.sbfi.admin.ch/h2020/index.html?lang=en.

Answer: 

There are no specific eligibility criteria in relation to a lead applicant other than the eligibility criteria specified in the call text. Please see the call text for specific requirements. Prior to signing the grant agreement, EDCTP will assess the capacity of the lead applicant’s institution to administer and manage the grant.

Answer: 

NID = Neglected Infectious Diseases, otherwise also known as Neglected Tropical Diseases.

Answer: 

The work plan for 2015 is currently being reviewed by the European Commission and EDCTP expects a decision no earlier than September 2015.

Answer: 

Third-party involvement can be mentioned in the body of the application but currently there are no specific fields requesting this information.
All technical questions regarding the application form should be addressed to edctpgrants@edctp.org directly, and for specific questions on the different types of participants to be added in a proposal, please contact the Project Officer (see name and e-mail in the Call Text) in charge of the Call.

Answer: 

It is correct that in case of applications in two stages, at the Letter of Intent stage there is no requirement to include figures, charts or other graphics in submitted proposals. In the Letter of Intent stage of this call, the only criteria that are used for the evaluation of the proposals are Excellence and Impact.

EDCTP aims to keep the Letter of Intent stage as simple as possible. At the second - full proposal – stage, the quality and efficiency of the implementation in addition to the Excellence and Impact criteria are evaluated. The application form will be equipped with upload functions where applicants can upload supporting documents such as charts.

In general, if attachments are required for a specific section of the Letter of Intent or the full proposal, the form will have the necessary upload function, e.g. for the call 'Strategic actions supporting large-scale clinical trials', cofunding letters can be uploaded and attached to the Letter of Intent.

Scope (4)

Question details: 
Will EDCTP under its second programme support early clinical development work such as clinical grade product development, manufacture of clinical grade materials, or early phase I clinical trials of vaccines and products?
Answer: 

Pre-clinical development cannot be supported by EDCTP. EDCTP only supports phase I to IV clinical trials. The grant that EDCTP provides, in case a proposal is successful, can be used in part to cover the costs associated with manufacturing a product that is necessary to conduct the clinical trial (phase I and beyond), on the condition that accounting conditions for recognising expenditures are met.
Under no circumstances can any (manufacturing) cost incurred before the start of the EDCTP-funded project, be counted as cofunding to the project (in case cofunding is requested). Requests for funding of early pre-clinical work can, for example, be directed to other Horizon2020 programmes.

Question details: 
What are the differences between the currently open call ‘Strategic actions supporting large scale trials’, and the already closed call ‘Diagnostic tools for poverty-related diseases’, also a RIA action with two stages?
Answer: 

The ‘Strategic actions’ call supports clinical research activities which are part of a large-scale clinical trial that has the potential to achieve rapid advances in the clinical development of new or improved medical interventions against poverty-related and neglected infectious diseases. In short, the ‘Strategic actions’ call focuses on large-scale clinical trials. The ‘Diagnostics’ call is intended to fund projects that aim to validate the clinical performance and/or implementation of new or improved diagnostic tools and technologies for the detection of any of the PRDs (including as co-infections).

Answer: 

It can be considered if it is presented as comorbidity with a poverty-related infectious disease within the remit of the call.

Answer: 

EDCTP provides funding for research on infectious diseases, especially poverty-related and neglected and/or emergent infectious diseases prevalent in sub-Saharan Africa.